Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea

Although travellers' diarrhoea can sometimes be associated with postinfectious complications, the condition is typically self-limiting. The infectious-diarrhoea guidelines subcommittees of the Infectious Disease Society of America and the American College of Gastroenterology recommend empirical...

Full description

Saved in:
Bibliographic Details
Published in:Drug safety 2006-01, Vol.29 (3), p.201-207
Main Author: ERICSSON, Charles D
Format: Article
Language:English
Subjects:
Anti-Infective Agents - adverse effects
Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Clinical Trials as Topic
Diarrhea - drug therapy
Gastrointestinal Agents - adverse effects
Gastrointestinal Agents - pharmacology
Gastrointestinal Agents - therapeutic use
Humans
Medical sciences
Pharmacology. Drug treatments
Rifamycins - adverse effects
Rifamycins - pharmacology
Rifamycins - therapeutic use
Travel
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although travellers' diarrhoea can sometimes be associated with postinfectious complications, the condition is typically self-limiting. The infectious-diarrhoea guidelines subcommittees of the Infectious Disease Society of America and the American College of Gastroenterology recommend empirical antibacterial therapy for travellers' diarrhoea. Because therapy is directed largely at relieving symptoms and minimising inconvenience, the chosen antibacterial should ideally be both efficacious and pose a low risk of adverse effects. This review discusses the safety and tolerability of rifaximin in the treatment of travellers' diarrhoea, with a focus on data from controlled clinical trials. Data were obtained from a MEDLINE search using the key word 'rifaximin' with no date limits and from the rifaximin New Drug Application submitted to the US FDA for approval to market rifaximin in the US.Currently, the antibacterials considered as standard treatment for travellers' diarrhoea are systemically absorbed, carry defined risks of adverse effects, and have many uses other than the treatment of enteric disease. The minimally absorbed (
ISSN:0114-5916
DOI:10.2165/00002018-200629030-00004